619 related articles for article (PubMed ID: 28356247)
1. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
Nayak L; Iwamoto FM; LaCasce A; Mukundan S; Roemer MGM; Chapuy B; Armand P; Rodig SJ; Shipp MA
Blood; 2017 Jun; 129(23):3071-3073. PubMed ID: 28356247
[TBL] [Abstract][Full Text] [Related]
2. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma.
Terziev D; Hutter B; Klink B; Stenzinger A; Stögbauer F; Glimm H; Fröhling S; Wickenhauser C; Jordan K; Hurtz HJ; Müller LP; Rüssel J; Weber T
Eur J Haematol; 2018 Jul; 101(1):115-118. PubMed ID: 29624748
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
[TBL] [Abstract][Full Text] [Related]
5. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY; Zhou J; Young KH
Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
[TBL] [Abstract][Full Text] [Related]
6. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
7. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
Haverkos BM; Abbott D; Hamadani M; Armand P; Flowers ME; Merryman R; Kamdar M; Kanate AS; Saad A; Mehta A; Ganguly S; Fenske TS; Hari P; Lowsky R; Andritsos L; Jagasia M; Bashey A; Brown S; Bachanova V; Stephens D; Mineishi S; Nakamura R; Chen YB; Blazar BR; Gutman J; Devine SM
Blood; 2017 Jul; 130(2):221-228. PubMed ID: 28468799
[TBL] [Abstract][Full Text] [Related]
8. Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Chapuy B; Roemer MG; Stewart C; Tan Y; Abo RP; Zhang L; Dunford AJ; Meredith DM; Thorner AR; Jordanova ES; Liu G; Feuerhake F; Ducar MD; Illerhaus G; Gusenleitner D; Linden EA; Sun HH; Homer H; Aono M; Pinkus GS; Ligon AH; Ligon KL; Ferry JA; Freeman GJ; van Hummelen P; Golub TR; Getz G; Rodig SJ; de Jong D; Monti S; Shipp MA
Blood; 2016 Feb; 127(7):869-81. PubMed ID: 26702065
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
Ansell SM; Minnema MC; Johnson P; Timmerman JM; Armand P; Shipp MA; Rodig SJ; Ligon AH; Roemer MGM; Reddy N; Cohen JB; Assouline S; Poon M; Sharma M; Kato K; Samakoglu S; Sumbul A; Grigg A
J Clin Oncol; 2019 Feb; 37(6):481-489. PubMed ID: 30620669
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
Merryman RW; Kim HT; Zinzani PL; Carlo-Stella C; Ansell SM; Perales MA; Avigdor A; Halwani AS; Houot R; Marchand T; Dhedin N; Lescaut W; Thiebaut-Bertrand A; François S; Stamatoullas-Bastard A; Rohrlich PS; Labussière Wallet H; Castagna L; Santoro A; Bachanova V; Bresler SC; Srivastava A; Kim H; Pesek E; Chammas M; Reynolds C; Ho VT; Antin JH; Ritz J; Soiffer RJ; Armand P
Blood; 2017 Mar; 129(10):1380-1388. PubMed ID: 28073785
[TBL] [Abstract][Full Text] [Related]
11. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
14. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.
Jelinek T; Mihalyova J; Kascak M; Duras J; Hajek R
Immunology; 2017 Nov; 152(3):357-371. PubMed ID: 28685821
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
17. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.
de-la-Fuente C; Nuñez F; Cortés-Romera M; Franch-Sarto M; Ribera JM; Sancho JM
Hematol Oncol; 2021 Aug; 39(3):419-422. PubMed ID: 33369766
[TBL] [Abstract][Full Text] [Related]
20. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I
J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
